Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Michael Szarek

Concepts (315)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Acute Coronary Syndrome
38
2025
297
6.150
 Why?
Anticholesteremic Agents
31
2026
155
5.440
 Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
42
2026
444
5.060
 Why?
Antibodies, Monoclonal, Humanized
45
2025
992
4.200
 Why?
Cholesterol, LDL
47
2026
360
3.520
 Why?
Lipoprotein(a)
18
2026
69
3.320
 Why?
Glycosides
13
2026
43
2.440
 Why?
Peripheral Arterial Disease
16
2026
507
2.170
 Why?
Cardiovascular Diseases
29
2026
2190
2.150
 Why?
Heptanoic Acids
20
2014
67
1.600
 Why?
Dyslipidemias
9
2025
184
1.560
 Why?
Stroke
14
2022
1271
1.480
 Why?
Pyrroles
20
2014
220
1.470
 Why?
Myocardial Infarction
17
2024
1211
1.450
 Why?
Diabetes Mellitus, Type 2
17
2026
2602
1.310
 Why?
Ischemic Attack, Transient
4
2020
71
1.310
 Why?
Proprotein Convertase 9
19
2026
87
1.290
 Why?
Rivaroxaban
14
2026
271
1.260
 Why?
Double-Blind Method
38
2026
2064
1.200
 Why?
Treatment Outcome
62
2026
11793
1.190
 Why?
Platelet Aggregation Inhibitors
12
2026
499
1.140
 Why?
Hyperlipoproteinemia Type II
5
2026
32
1.120
 Why?
Atherosclerosis
7
2026
409
1.050
 Why?
Cholesterol Ester Transfer Proteins
6
2026
22
1.040
 Why?
Eicosapentaenoic Acid
2
2025
37
1.030
 Why?
Angina, Unstable
7
2019
83
0.940
 Why?
Heart Failure
9
2026
2326
0.880
 Why?
Brain Ischemia
7
2022
359
0.860
 Why?
Hypertriglyceridemia
1
2024
45
0.810
 Why?
Serine Proteinase Inhibitors
5
2025
48
0.800
 Why?
Lower Extremity
10
2026
445
0.770
 Why?
Factor Xa Inhibitors
8
2026
194
0.740
 Why?
Aged
70
2026
26212
0.710
 Why?
Antibodies, Monoclonal
5
2023
1505
0.690
 Why?
Middle Aged
67
2026
36297
0.670
 Why?
Humans
123
2026
145750
0.660
 Why?
Renal Insufficiency, Chronic
6
2025
668
0.640
 Why?
Aspirin
11
2026
406
0.630
 Why?
Drug Therapy, Combination
14
2026
1044
0.620
 Why?
Hypercholesterolemia
7
2020
95
0.600
 Why?
Carcinoma, Renal Cell
1
2021
230
0.560
 Why?
Male
81
2026
72992
0.540
 Why?
Patient Admission
1
2019
220
0.520
 Why?
Simvastatin
4
2010
59
0.510
 Why?
Female
79
2026
79025
0.510
 Why?
Kidney Neoplasms
1
2021
414
0.490
 Why?
Risk Factors
21
2026
10916
0.450
 Why?
Vascular Surgical Procedures
3
2026
343
0.450
 Why?
Biomarkers
15
2026
4302
0.420
 Why?
Endovascular Procedures
3
2026
390
0.410
 Why?
Patient Readmission
1
2019
772
0.400
 Why?
Venous Thromboembolism
3
2023
328
0.390
 Why?
Global Health
3
2021
403
0.380
 Why?
RNA, Small Interfering
2
2026
638
0.380
 Why?
Life Change Events
1
2014
147
0.380
 Why?
Ischemia
5
2022
422
0.380
 Why?
Triglycerides
3
2024
520
0.370
 Why?
Secondary Prevention
5
2019
251
0.360
 Why?
Career Choice
1
2014
235
0.350
 Why?
Time Factors
12
2026
7133
0.340
 Why?
Cholesterol, HDL
6
2025
201
0.340
 Why?
Markov Chains
2
2010
132
0.340
 Why?
Apolipoproteins B
7
2026
47
0.340
 Why?
Risk Assessment
9
2025
3752
0.330
 Why?
Coronary Artery Bypass
2
2025
268
0.320
 Why?
Phospholipids
3
2025
214
0.320
 Why?
Cholesterol
3
2022
408
0.310
 Why?
Thrombosis
2
2025
400
0.300
 Why?
Randomized Controlled Trials as Topic
7
2026
1751
0.290
 Why?
Follow-Up Studies
9
2026
5428
0.290
 Why?
Students, Medical
1
2014
378
0.290
 Why?
Ezetimibe
2
2026
24
0.280
 Why?
Coronary Disease
5
2009
382
0.280
 Why?
Infectious Disease Transmission, Vertical
1
2010
194
0.280
 Why?
Rosuvastatin Calcium
3
2026
21
0.270
 Why?
Apolipoproteins
3
2025
38
0.260
 Why?
Apolipoprotein B-100
2
2025
13
0.250
 Why?
Albuminuria
3
2024
189
0.250
 Why?
Lipoproteins, VLDL
1
2026
21
0.240
 Why?
Receptors, Urokinase Plasminogen Activator
1
2026
15
0.240
 Why?
Models, Statistical
1
2010
672
0.240
 Why?
Receptors, LDL
1
2026
53
0.240
 Why?
Hemorrhage
7
2026
822
0.230
 Why?
Hyperlipoproteinemia Type III
1
2025
4
0.230
 Why?
Proportional Hazards Models
9
2019
1330
0.230
 Why?
Saphenous Vein
1
2025
37
0.220
 Why?
Graft Occlusion, Vascular
1
2025
40
0.220
 Why?
Vascular Patency
1
2025
121
0.220
 Why?
Survival Analysis
1
2008
1378
0.210
 Why?
tau Proteins
1
2025
105
0.210
 Why?
HIV-1
1
2010
908
0.210
 Why?
Anticoagulants
4
2023
748
0.200
 Why?
Glomerular Filtration Rate
2
2024
765
0.190
 Why?
Primary Health Care
1
2014
1736
0.190
 Why?
Internship and Residency
1
2014
1269
0.190
 Why?
Fibrin Fibrinogen Degradation Products
1
2023
92
0.190
 Why?
Hyperlipidemias
1
2003
120
0.190
 Why?
Apolipoproteins E
2
2025
93
0.190
 Why?
Antifibrinolytic Agents
1
2023
64
0.180
 Why?
Muscles
1
2022
330
0.170
 Why?
Blood Coagulation Disorders
1
2023
198
0.160
 Why?
Hospitalization
6
2023
2460
0.160
 Why?
Cataract
1
2023
238
0.160
 Why?
Phenylurea Compounds
1
2021
119
0.160
 Why?
Quinolines
1
2021
190
0.150
 Why?
Kidney Diseases
1
2023
426
0.150
 Why?
Renal Insufficiency
1
2021
172
0.150
 Why?
Colonic Neoplasms
1
2021
258
0.150
 Why?
Health Status
1
2024
835
0.140
 Why?
Patient Care Team
1
2024
697
0.140
 Why?
Multifactorial Inheritance
1
2019
209
0.140
 Why?
Liver X Receptors
1
2018
29
0.140
 Why?
Venous Thrombosis
1
2020
196
0.130
 Why?
Diabetes Complications
1
2019
225
0.130
 Why?
Lipids
4
2010
707
0.130
 Why?
Dose-Response Relationship, Drug
6
2021
2028
0.130
 Why?
Neoplasms, Experimental
1
2018
167
0.130
 Why?
Cost-Benefit Analysis
1
2020
644
0.130
 Why?
Myeloid-Derived Suppressor Cells
1
2018
76
0.120
 Why?
Prospective Studies
8
2022
8075
0.120
 Why?
Pyrans
2
2026
7
0.120
 Why?
Diabetes Mellitus, Type 1
2
2023
3937
0.120
 Why?
Myocardial Ischemia
3
2007
285
0.110
 Why?
Atrial Fibrillation
1
2022
558
0.110
 Why?
Adult
16
2026
40867
0.110
 Why?
HIV Infections
1
2010
3195
0.110
 Why?
Heterozygote
2
2026
314
0.110
 Why?
Hospital Mortality
1
2019
1038
0.110
 Why?
Proprotein Convertases
1
2014
16
0.110
 Why?
Killer Cells, Natural
1
2018
481
0.110
 Why?
Receptors, Interleukin-3
1
2014
5
0.110
 Why?
C-Reactive Protein
3
2022
423
0.110
 Why?
Immunotherapy, Adoptive
1
2018
342
0.100
 Why?
Neoplasm Recurrence, Local
1
2021
1150
0.100
 Why?
Antigens, Neoplasm
2
2006
271
0.100
 Why?
Hypoglycemic Agents
4
2024
1399
0.100
 Why?
Disease-Free Survival
2
2018
770
0.100
 Why?
Skin Neoplasms
2
2014
852
0.100
 Why?
Colorectal Neoplasms
1
2021
868
0.100
 Why?
Coronary Artery Disease
1
2019
750
0.100
 Why?
Aged, 80 and over
8
2026
8346
0.100
 Why?
Clinical Trials as Topic
3
2008
1062
0.090
 Why?
Hematologic Neoplasms
1
2014
168
0.090
 Why?
Injections, Subcutaneous
2
2024
170
0.090
 Why?
Neoplasms
2
2023
2913
0.090
 Why?
Immunity, Innate
1
2018
835
0.090
 Why?
Developing Countries
1
2014
317
0.090
 Why?
Clinical Decision-Making
1
2015
364
0.090
 Why?
Recombinant Fusion Proteins
1
2014
666
0.080
 Why?
Diabetes Mellitus
1
2020
1101
0.080
 Why?
Heparin
2
2023
247
0.080
 Why?
Leukemia, Myeloid, Acute
1
2018
688
0.080
 Why?
Sodium-Glucose Transporter 1
2
2020
11
0.080
 Why?
Urban Population
1
2014
494
0.080
 Why?
Bottle Feeding
1
2010
19
0.080
 Why?
Norway
1
2010
41
0.080
 Why?
Stroke Volume
2
2024
655
0.080
 Why?
Dendritic Cells
1
2014
500
0.080
 Why?
Denmark
1
2010
51
0.080
 Why?
Netherlands
1
2010
84
0.080
 Why?
Finland
1
2010
78
0.080
 Why?
Serum Amyloid A Protein
2
2007
32
0.080
 Why?
Arteries
2
2022
261
0.080
 Why?
Likelihood Functions
1
2010
138
0.080
 Why?
Sweden
1
2010
115
0.080
 Why?
Antineoplastic Agents
1
2021
2219
0.080
 Why?
Risk
6
2008
923
0.080
 Why?
Probability
1
2010
308
0.080
 Why?
Myocardial Revascularization
1
2009
85
0.070
 Why?
Statistics, Nonparametric
1
2010
428
0.070
 Why?
Hydroxymethylglutaryl CoA Reductases
1
2009
13
0.070
 Why?
Melanoma
2
2006
761
0.070
 Why?
Biomarkers, Tumor
2
2006
1329
0.070
 Why?
United States Government Agencies
1
2008
5
0.070
 Why?
Practice Guidelines as Topic
3
2019
1582
0.070
 Why?
Oxidation-Reduction
3
2025
1068
0.070
 Why?
Biometry
1
2008
66
0.070
 Why?
Inflammation
4
2023
2883
0.060
 Why?
Tissue Plasminogen Activator
2
2022
248
0.060
 Why?
Counseling
1
2010
401
0.060
 Why?
Cell Line, Tumor
3
2021
3551
0.060
 Why?
Incidence
3
2022
2933
0.060
 Why?
Recurrence
4
2019
1139
0.060
 Why?
Postoperative Complications
1
2019
2977
0.060
 Why?
Breast Feeding
1
2010
447
0.060
 Why?
Oxazolidinones
1
2026
17
0.060
 Why?
Decision Making
1
2014
981
0.060
 Why?
United States
3
2019
16122
0.060
 Why?
Data Interpretation, Statistical
1
2008
368
0.060
 Why?
Reactive Oxygen Species
1
2009
611
0.060
 Why?
Fibrinolytic Agents
2
2022
297
0.060
 Why?
Predictive Value of Tests
3
2025
2123
0.060
 Why?
Limb Salvage
1
2026
73
0.060
 Why?
Dicarboxylic Acids
1
2025
12
0.060
 Why?
Acute Disease
3
2021
1036
0.060
 Why?
Clinical Trials, Phase III as Topic
1
2025
116
0.060
 Why?
Natriuretic Peptide, Brain
1
2026
109
0.060
 Why?
Esters
1
2025
71
0.060
 Why?
Cancer Vaccines
1
2006
162
0.050
 Why?
Medication Adherence
1
2009
540
0.050
 Why?
Lipoproteins, HDL
1
2005
100
0.050
 Why?
Antigen-Antibody Complex
1
2004
69
0.050
 Why?
CD40 Ligand
1
2004
40
0.050
 Why?
Lipoproteins, LDL
1
2004
119
0.050
 Why?
Subtilisins
1
2023
9
0.050
 Why?
Thromboplastin
1
2023
67
0.050
 Why?
Severity of Illness Index
2
2026
2933
0.050
 Why?
Fatty Acids
1
2025
457
0.040
 Why?
Creatine Kinase
1
2022
72
0.040
 Why?
Numbers Needed To Treat
1
2021
7
0.040
 Why?
Peptide Fragments
1
2026
696
0.040
 Why?
Plasma Membrane Neurotransmitter Transport Proteins
1
2021
6
0.040
 Why?
Pharmacogenomic Testing
1
2022
63
0.040
 Why?
Metabolic Syndrome
1
2005
361
0.040
 Why?
Inflammation Mediators
1
2004
507
0.040
 Why?
Creatine
1
2021
63
0.040
 Why?
Precision Medicine
1
2025
461
0.040
 Why?
Receptors, Immunologic
1
2022
209
0.040
 Why?
Goals
1
2022
185
0.040
 Why?
Mice
3
2026
18357
0.040
 Why?
Proto-Oncogene Proteins p21(ras)
1
2021
254
0.040
 Why?
Membrane Transport Proteins
1
2021
154
0.040
 Why?
Algorithms
1
2008
1850
0.040
 Why?
Diabetic Nephropathies
1
2024
322
0.040
 Why?
Disease Progression
2
2024
2865
0.040
 Why?
Mycoses
1
2020
88
0.040
 Why?
Placebo Effect
1
2019
24
0.040
 Why?
Ventricular Function, Left
1
2023
544
0.040
 Why?
Mice, Nude
1
2021
680
0.040
 Why?
Odds Ratio
3
2009
1083
0.040
 Why?
Hypotension
1
2020
127
0.040
 Why?
Diarrhea
1
2020
193
0.040
 Why?
Age Factors
1
2007
3346
0.040
 Why?
Patient Education as Topic
1
2024
777
0.040
 Why?
Antigens, CD
1
2022
558
0.040
 Why?
Propensity Score
1
2021
377
0.040
 Why?
Sex Characteristics
1
2024
789
0.030
 Why?
Transplantation, Haploidentical
1
2018
23
0.030
 Why?
Sex Factors
1
2024
2110
0.030
 Why?
Diabetic Ketoacidosis
1
2020
210
0.030
 Why?
Nerve Tissue Proteins
1
2021
592
0.030
 Why?
American Heart Association
1
2019
358
0.030
 Why?
Cell Count
1
2018
319
0.030
 Why?
Mice, SCID
1
2018
369
0.030
 Why?
Muscular Diseases
2
2008
109
0.030
 Why?
Erythrocytes
1
2022
749
0.030
 Why?
Cohort Studies
2
2022
6032
0.030
 Why?
Vascular Diseases
1
2019
252
0.030
 Why?
Morbidity
1
2017
322
0.030
 Why?
Infant
1
2010
10089
0.030
 Why?
Liver
1
2024
1899
0.030
 Why?
Mice, Inbred NOD
1
2018
616
0.030
 Why?
Kidney
1
2024
1498
0.030
 Why?
Immunoglobulin M
2
2009
265
0.030
 Why?
Membrane Proteins
1
2022
1166
0.030
 Why?
Animals
3
2026
38100
0.030
 Why?
Genome-Wide Association Study
1
2022
1430
0.030
 Why?
Cytoplasm
2
2006
254
0.030
 Why?
Cause of Death
1
2017
471
0.030
 Why?
Tissue Donors
1
2018
420
0.030
 Why?
Fluorobenzenes
1
2014
17
0.030
 Why?
Xenograft Model Antitumor Assays
1
2018
936
0.030
 Why?
Interleukin-3
1
2014
23
0.030
 Why?
Syndrome
2
2007
381
0.030
 Why?
Diphtheria Toxin
1
2014
65
0.030
 Why?
Cell Proliferation
1
2021
2514
0.030
 Why?
Thrombolytic Therapy
1
2015
164
0.030
 Why?
Serine Endopeptidases
1
2014
129
0.020
 Why?
Multivariate Analysis
2
2007
1547
0.020
 Why?
Immunoglobulin G
2
2009
892
0.020
 Why?
Acute Kidney Injury
1
2020
875
0.020
 Why?
Prognosis
3
2005
4329
0.020
 Why?
Quality of Life
1
2024
3210
0.020
 Why?
Child, Preschool
2
2005
11866
0.020
 Why?
Neoplasm Staging
2
2006
1474
0.020
 Why?
CD8-Positive T-Lymphocytes
1
2018
923
0.020
 Why?
Interleukin-6
2
2007
779
0.020
 Why?
Molecular Targeted Therapy
1
2014
440
0.020
 Why?
Pyrimidines
1
2014
530
0.020
 Why?
Adolescent
3
2006
22569
0.020
 Why?
Mice, Knockout
1
2018
3130
0.020
 Why?
Sulfonamides
1
2014
583
0.020
 Why?
Mutation
1
2021
4090
0.020
 Why?
Autoantibodies
2
2009
1509
0.020
 Why?
Pilot Projects
1
2015
1897
0.020
 Why?
Ireland
1
2008
32
0.020
 Why?
Apolipoprotein A-I
1
2008
39
0.020
 Why?
Europe
1
2009
421
0.020
 Why?
Thromboembolism
1
2009
129
0.020
 Why?
Lipoproteins
1
2009
166
0.020
 Why?
United Kingdom
1
2008
358
0.020
 Why?
Child
2
2005
22738
0.020
 Why?
Drug Prescriptions
1
2009
288
0.020
 Why?
Cerebral Infarction
1
2006
47
0.020
 Why?
Gastrointestinal Diseases
1
2008
222
0.010
 Why?
Hematuria
1
2005
11
0.010
 Why?
Immunotherapy, Active
1
2005
9
0.010
 Why?
ROC Curve
1
2007
618
0.010
 Why?
Aspartate Aminotransferases
1
2005
85
0.010
 Why?
Cerebral Hemorrhage
1
2006
125
0.010
 Why?
Alanine Transaminase
1
2005
151
0.010
 Why?
Drug Utilization
1
2005
168
0.010
 Why?
Drug Administration Schedule
1
2007
782
0.010
 Why?
Arteriosclerosis
1
2004
83
0.010
 Why?
Chemical and Drug Induced Liver Injury
1
2005
138
0.010
 Why?
Angina Pectoris
1
2004
76
0.010
 Why?
Enzyme-Linked Immunosorbent Assay
1
2006
849
0.010
 Why?
Solubility
1
2004
240
0.010
 Why?
Troponin
1
2003
50
0.010
 Why?
Research Design
1
2009
1139
0.010
 Why?
Databases, Factual
1
2008
1491
0.010
 Why?
Heart Arrest
1
2004
411
0.010
 Why?
Pain
1
2005
791
0.010
 Why?
Retrospective Studies
2
2007
17322
0.010
 Why?
Brain
1
2007
2969
0.010
 Why?
Szarek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (315) concept(s)
_
Co-Authors Expand Description
See all (9) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)